INTRODUCTION
Lymphomas account for approximately 5-6% of all malignancies. 1 Over two-thirds of these cases are non-Hodgkin lymphomas (NHL), and Hodgkin's lymphoma (HL) makes up the rest. 1 After a histopathological diagnosis has been established, the imaging-based initial staging will influence the choice of therapy and prognosis, aid in radiation therapy planning for localized disease and provide a baseline for treatment response monitoring. 2, 3 HL and NHL staging is currently based on the Cotswolds modification of the Ann Arbor classification system. 4 This system uses the number of tumor sites, the extent of involvement (nodal or extranodal) and its distribution as staging factors, whereas the Cotswolds modification also takes tumor burden into account.
Several imaging methods have been used for this purpose and, of these, computed tomography (CT) is currently the most popular. 2, 3 Over recent years, [18] F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/ CT) has emerged as the most accurate method of all. It is based on the principle that malignant tissues exhibit higher glucose metabolism than that of healthy tissue 5 and enables whole-body scanning with high sensitivity for detection of affected areas while combining the anatomical and functional assessment capabilities of CT and PET. 6, 7 However, its sensitivity and specificity vary according to histological subtype, 8, 9 and use of PET/CT has been correlated with substantial radiation exposure, particularly because scans must often be obtained repeatedly over the treatment course. Recent studies have shown that radiation exposure secondary to diagnostic imaging leads to increased lifetime risk of malignant tumors, especially in children. [10] [11] [12] Magnetic resonance imaging (MRI) has emerged as a safer alternative for lymphoma staging, since progress in MRI techniques now enables rapid whole-body scanning 13 while potentially providing the same information as FDG-PET/CT. 14, 15 The functional assessment in whole-body MRI (WB-MRI) is based on diffusion-weighted imaging (DWI), a method that maps water molecule movement in tissue (within cells, in the extracellular medium and across cell membranes). In the presence of lymphomas, the Brownian motion of water molecules is restricted due to increased tissue cellularity and elevated nucleus-to-cytoplasm ratio, which will produce relatively high signal intensity on DWI, compared with normal tissues. 16 Using this principle, diffusion MRI can detect tumor-related changes that are not limited to anatomical information. 17 Furthermore, apparent diffusion coefficient (ADC) quantification on DWI can provide useful information on treatment response and help distinguish benign from malignant lymph nodes. 18 Over the last decade, a growing number of studies have compared WB-MRI and FDG-PET/CT in patients with lymphoma, using a variety of approaches. In studies focusing solely on initial lymphoma staging, the two methods are usually compared in two ways: taking into account the accuracy of each method for detection of individual lesions (on the basis of the number of lesions detected); or taking into account the final staging score, regardless of the number of lesions detected through each method.
Comparative analysis on these studies can be quite challenging when this attempts to focus on the ability of each method to detect individual lesions. The difficulty is mostly due to the wide range of WB-MRI protocols used, which precludes proper comparison. However, since the ultimate objective of initial lymphoma imaging is to define the disease stage at baseline, studies can be compared on the basis of the staging scores indicated by each method, regardless of the number of lesions detected.
OBJECTIVES
Within this context, this study aimed to compare whole-body diffusion-weighted MRI (WB-MRI) with PET/CT for lymphoma staging by means of a meta-analysis, in order to identify whether the data available in the literature are sufficient to establish that WB-MRI is a safe alternative for lymphoma staging.
METHODS

Type of study and participants
This was a systematic review of diagnostic test accuracy studies, with meta-analysis. The spectrum of patients included HL and NHL cases.
The present study was approved by the local Research Ethics
Committee, under number 0135/12HE.
Inclusion criteria
All diagnostic test accuracy studies, comparing WB-MRI versus FDG-PET/CT for initial lymphoma staging, with the added utility of DWI in WB-MRI, which were published up to September 2013, were assessed.
Exclusion criteria
Studies meeting any of the following criteria were excluded: data could only be extracted for one of the methods under analysis; FDG-PET/CT was used as the single reference standard for lymphoma staging; samples included cases previously reported elsewhere; the data represented a subpopulation analysis from larger investigations previously included in our review; the study included patients with diseases other than lymphoma; or the study assessed the performance of WB-MRI in relation to lymphomas, but only for detection of bone involvement.
Search strategy
The Medline (via PubMed), Embase, Lilacs and Scopus databases were searched for relevant studies on the performance of WB-MRI versus other imaging methods for lymphoma evaluation. The references of each study included were checked for potentially relevant additional citations. The results from our search strategy are shown in Table 1 . The search was last updated on September 27, 2013.
Article selection and quality assessment
For the first stage of the selection, two investigators (RR, AP)
conducted independent assessments of the titles and abstracts of articles identified by the abovementioned search strategy.
Studies on the diagnostic performance of WB-MRI for lymphoma staging or follow-up were included. Animal studies, reviews, meta-analyses, abstracts, editorials, letters to the editor, case reports, tutorials and practice guidelines were excluded. All clearly ineligible articles were also excluded.
For the second stage, all potentially eligible studies were set aside for full-text reading, critical appraisal and data extraction, conducted independently by the same investigators (RR, AP).
Any disagreements arising between them at either stage were resolved through discussion and reaching a consensus.
Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). 19 The QUADAS-2 tool enables more transparent ratings for bias and for the applicability of diagnostic accuracy studies. Three responses to questions regarding the risk of bias and applicability concerns were possible: "low", "high" or "unclear".
Reference standard
Lymphoma 
RESULTS
The search strategy chosen yielded 929 citations. On completion of the search and retrieval strategy, six prospective cohort studies were included for meta-analysis. [14] [15] [16] [34] [35] [36] Most of them either failed to conduct separate analyses on HL and NHL or conducted pooled analyses on different histological subtypes of NHL. The study by Wu et al. 34 limited its analysis only to a single histological subtype of NHL. Note: all synonyms under the hierarchical tree of each term were also included for each database.
Quality assessment on studies included Figure 1 summarizes the risk of bias and applicability judgments on the six studies included. The methodological quality graph presents the percentage of included studies for which the item was rated "low", "high" or "unclear", for each quality assessment domain. The graph shows that the potential area of concern was the description of the reference standard.
Patient selection criteria were clearly described in all the studies included. Regarding the reference standard, van Ufford et al. 35 and Lin et al. 36 did not describe it clearly. All the other quality assessment parameters were considered satisfactory across all six studies.
The QUADAS-2 score, expressed as a percentage of the maximum score, was 90% on average (range, 71-100%) in the six studies included. In the quality assessment, all of the studies were considered to present low risk of bias and low concerns about applicability.
Summary assessment of the sensitivity of WB-MRI for lymphoma staging
The sensitivity of WB-MRI and FDG-PET/CT for initial lymphoma staging versus that of the reference standard ranged from 59% to 100% and from 63% to 100% respectively (Figure 2) .
Gu et al., 14 Abdulqadhr et al., 15 Stéphane et al. 16 and Lin et al. reported high sensitivity for both methods, whereas Wu et al. 34 and van Ufford et al. 35 found lower sensitivity values.
Agreement between WB-MRI and FDG-PET/CT for lymphoma staging
In the study by Gu et al., 14 there was agreement between WB-MRI and FDG-PET/CT staging in 15 of their 17 patients.
In the remaining two patients, WB-MRI overstaged one and understaged the other. In the latter patient, the staging with both methods was considered inadequate in relation to the reference standard because both of them failed to detect bone marrow infiltration, which was later confirmed by means of bone marrow biopsy. In the study by Abdulqadhr et al., 15 there was agreement between WB-MRI and FDG-PET/CT staging in 28 of their 31
patients. In the remaining three patients, low-grade lymphoma had higher staging through WB-MRI than through FDG-PET/ CT, which was later validated by means of clinical staging. In the studies by Stéphane et al. 16 and Wu et al. 34 WB-MRI and FDG-PET/CT yielded the same staging in all patients, although three were incorrectly staged with both methods in the study by Wu et al. 34 In the sample of van Ufford et al., 35 Table 3 . Agreement between WB-MRI and FDG-PET/CT for lymphoma staging in each of the studies included Head, neck, chest, abdomen, pelvis, proximal thigh SPAIR = spectral presaturation attenuated inversion recovery; STIR = short tau inversion recovery; DWI = diffusion-weighted imaging; SAT = fat saturation; ADC = apparent diffusion coefficient; MIP = maximum intensity projection; WB-MRI = whole-body diffusion-weighted magnetic resonance imaging. Table 4 . WB-MRI protocols used in studies included in the meta-analysis WB-MRI and FDG-PET/CT in 105 cases (90.5%). In nearly all cases of differences in staging, WB-MRI yielded a higher grade than FDG-PET/CT. Overall, there was excellent agreement between the two methods (κ = 0.871; P < 0.0001).
Some characteristics inherent to WB-MRI may lead to falsepositive results, such as its limited ability to distinguish malignant from benign causes of lymph node enlargement, particularly in inguinal and axillary nodes, and its extreme sensitivity for small lymph nodes, even on DWI sequences, 14 as well as the T2 shinethrough effect, which refers to an area of high signal on DWI mimicking restricted diffusion due to very prolonged spin-spin relaxation time. 34 In such cases, ADC quantitative analysis can be helpful for reducing the number of false positives in these cases. The causes of false-negative findings inherent to WB-MRI include diaphragmatic motion artifacts 37, 38 and artifacts in the hilar region due to respiratory and cardiac motion, 35 as well as falsely elevated ADC values in these areas. 25 Stéphane et al. 16 also reported difficulties in analyzing hilar regions.
Several intrinsic factors may hinder interpretation of FDG-
PET/CT results. Non-pathological variability in FDG uptake by healthy tissues, FDG uptake attributable to inflammation, altered biodistribution of FDG due to hyperglycemia or hyperinsulinemia and, particularly, the bone marrow activation commonly found in cancer patients after treatment may lead to false positives. 34 Addition of DWI to WB-MRI protocols provides improved lymph node viewing, compared with conventional sequences, thus increasing the accuracy of the method for detection of lesions, 14 whereas ADC value analysis improves specificity. In the study by Lin et al., 36 DWI using the lesion size criterion yielded sensitivity and specificity of 90% and 94% respectively, in comparison with FDG-PET/CT. Addition of visual ADC analysis reduced the sensitivity to 81% and increased the specificity to approximately 100%. ADC quantification can also provide useful information on treatment response. 18 In the study by Lin et al., 36 Since this reference standard establishes the definitive baseline staging that will be used for patient management and treatment planning, it may be considered to be the true measurement.
Therefore, we were able to calculate the sensitivity of the index methods as used in each of the studies included and compare them with the reference standard, i.e. to ascertain the ability of each method to stage the target condition correctly in relation to a true measurement. 40 We found that both WB-MRI and FDG-PET/CT exhibited high sensitivity in the studies by Gu et al., 14 Abdulqadhr et al. 15 and Lin et al., 36 ranging from 88 to 100% for WB-MRI and 90 to 94% for FDG-PET/CT. The highest sensitivity (100% for both methods) was found in the study by Stéphane et al. 16 In the study by Wu et al., 34 because of a poorly representative patient spectrum and because both methods staged three out of the eight patients incorrectly, the overall sensitivity was 63%.
In the study by van Ufford et al., 35 the sensitivity of WB-MRI was 59%, and that of FDG-PET/CT, 73%.
One limitation of the present review derives from the use of a clinical and radiological reference standard. Stéphane et al. 16 used FDG-PET/CT as the gold standard method, although they also explicitly used clinical and imaging follow-up data to set up the differences between WB-MRI and FDG-PET/CT. Gu et al. WB-MRI provides several advantages over FDG-PET/CT. It does not emit ionizing radiation, which is particularly useful in children and young adults 41, 42 and when patients must undergo repeated imaging for follow-ups, as in lymphoma cases. FDG-PET/CT exposes patients to substantial radiation doses and, consequently, is associated with increased risk of later malignancies. 42 Furthermore, thorough patient preparation is required before FDG-PET/CT, and because a cyclotron is required to produce FDG, it is not widely available. 
